Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could mixing HPV vaccines offer better protection?

NCT ID NCT07281677

Prevention Sponsor: Zhejiang Provincial Center for Disease Control and Prevention Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether giving girls aged 9-14 two different HPV vaccines in a sequence is safe and boosts immunity. The researchers will measure antibody levels and side effects in 400 participants. The goal is to see if this approach can improve protection against HPV, which causes cervical cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HPV vaccines (bivalent and 9-valent)
What this could lead to
If successful, this could show that using different HPV vaccines in sequence is a safe and effective way to protect against more types of HPV, potentially improving cervical cancer prevention.
What could go wrong
This is a Phase 4 study with 400 girls, so results may not apply to all populations. The main focus is on immune response and safety, not long-term cancer prevention, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

400 people

The number who actually took part.

Started

Dec 2025

Expected to finish

Nov 2029

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

9 to 14 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Have not received any HPV vaccine products. * Girls aged 9 to 14 years. * Reside permanently at the research site. Both the participant and her legal guardian have voluntarily agreed to participate, have signed the informed consent form, understand and agree to comply with the study protocol, and are able to complete all scheduled blood collections and follow-up visits. Exclusion Criteria * Suspected or confirmed fever (≥38.5°C) within 72 hours prior to enrollment, or axillary temperature \>37.0°C on the day of enrollment. * HIV infection or other immunocompromising conditions. * Presence of acute illness or being in the acute phase of a chronic disease. * History of severe allergic reactions to any component of the study vaccine or to previous vaccinations. * Contraindications to intramuscular injection, such as thrombocytopenia, coagulation disorders, or current anticoagulant therapy. * Receipt of non-live vaccines within 14 days or live attenuated vaccines within 28 days prior to HPV vaccination in this study. * Receipt of blood or blood-derived products within 3 months prior to enrollment, or planned use within 6 months from the first vaccination to completion of the full vaccination schedule. * Any disease or condition deemed by the investigator to place the participant at unacceptable risk, prevent adherence to study requirements, or interfere with the assessment of vaccine responses.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HPV infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

human papilloma virus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HPV infection

Contacts and locations

Locations

  • Jinyun center for Disease Control and Prevention

    Lishui, Zhejiang, 321400, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.